| Name | Title | Contact Details |
|---|---|---|
Andreas Busch |
Chief Innovation Officer | Profile |
Avicanna is a diversified and vertically integrated Canadian bio-pharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments. Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna`s team of experts have developed and commercialized several industry leading product lines, including: Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and, RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data. With ongoing clinical trials on its medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna`s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company`s vision since its inception. Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp derived API and custom formulations.
Courtagen Life Sciences is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.
Solstice Neurosciences is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diosynth Biotechnology is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.